New Drug Approvals

FDA approves third oncology drug Rozlytrek (entrectinib) that targets a key genetic driver of cancer, rather than a specific type of tumor August 20, 2019 - (0)

FDA approves third oncology drug Rozlytrek (entrectinib) that targets a key genetic driver of cancer, rather than a specific type of tumor FDA also approves drug for second indication in a type of lung cancer The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose […]
FDA approves new antibiotic Xenleta (lefamulin) to treat community-acquired bacterial pneumonia August 20, 2019 - (0)
AK 3280 August 16, 2019 - (1)
Novobiocin, ノボビオシン; August 14, 2019 - (1)
Imipenem, イミペネム水和物 August 8, 2019 - (1)

Mobile Site | Full Site